Meningococcal Vaccines Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Meningococcal Vaccines Market
1.1. Definition and Scope
1.1.1. Definition of Meningococcal Vaccines
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Meningococcal Vaccines Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Meningococcal Vaccines Market By Type
1.2.3. Meningococcal Vaccines Market By Serotype
1.2.4. Meningococcal Vaccines Market By Age Group
1.2.5. Meningococcal Vaccines Market By End-User
1.2.6. Meningococcal Vaccines Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Meningococcal Vaccines Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Meningococcal Vaccines Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Meningococcal Vaccines Market By Type
5.1. Introduction
5.2. Meningococcal Vaccines Revenue By Type
5.2.1. Meningococcal Vaccines Revenue (USD Billion) and Forecast, By Type, 2020-2032
5.2.2. Polysaccharide Vaccines
5.2.2.1. Polysaccharide Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Conjugate Vaccines
5.2.3.1. Conjugate Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Combination Vaccines
5.2.4.1. Combination Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. Other Types
5.2.5.1. Other Types Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Meningococcal Vaccines Market By Serotype
6.1. Introduction
6.2. Meningococcal Vaccines Revenue By Serotype
6.2.1. Meningococcal Vaccines Revenue (USD Billion) and Forecast, By Serotype, 2020-2032
6.2.2. MenACWY
6.2.2.1. MenACWY Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. MenB & Manic
6.2.3.1. MenB & Manic Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. MenC
6.2.4.1. MenC Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. MenA
6.2.5.1. MenA Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.6. MenAC
6.2.6.1. MenAC Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Meningococcal Vaccines Market By Age Group
7.1. Introduction
7.2. Meningococcal Vaccines Revenue By Age Group
7.2.1. Meningococcal Vaccines Revenue (USD Billion) and Forecast, By Age Group, 2020-2032
7.2.2. Infants (0 to 2 years)
7.2.2.1. Infants (0 to 2 years) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Children And Adults (2 years & above)
7.2.3.1. Children And Adults (2 years & above) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. Meningococcal Vaccines Market By End-User
8.1. Introduction
8.2. Meningococcal Vaccines Revenue By End-User
8.2.1. Meningococcal Vaccines Revenue (USD Billion) and Forecast, By End-User, 2020-2032
8.2.2. Retail Pharmacies
8.2.2.1. Retail Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.3. Hospital Pharmacies
8.2.3.1. Hospital Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.4. Others
8.2.4.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 9. North America Meningococcal Vaccines Market By Country
9.1. North America Meningococcal Vaccines Market Overview
9.2. U.S.
9.2.1. U.S. Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
9.2.2. U.S. Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
9.2.3. U.S. Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
9.2.4. U.S. Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.3. Canada
9.3.1. Canada Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
9.3.2. Canada Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
9.3.3. Canada Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
9.3.4. Canada Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.4. North America PEST Analysis
CHAPTER 10. Europe Meningococcal Vaccines Market By Country
10.1. Europe Meningococcal Vaccines Market Overview
10.2. U.K.
10.2.1. U.K. Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
10.2.2. U.K. Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
10.2.3. U.K. Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
10.2.4. U.K. Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.3. Germany
10.3.1. Germany Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
10.3.2. Germany Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
10.3.3. Germany Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
10.3.4. Germany Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.4. France
10.4.1. France Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
10.4.2. France Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
10.4.3. France Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
10.4.4. France Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.5. Spain
10.5.1. Spain Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
10.5.2. Spain Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
10.5.3. Spain Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
10.5.4. Spain Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.6. Rest of Europe
10.6.1. Rest of Europe Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
10.6.2. Rest of Europe Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
10.6.3. Rest of Europe Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
10.6.4. Rest of Europe Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.7. Europe PEST Analysis
CHAPTER 11. Asia Pacific Meningococcal Vaccines Market By Country
11.1. Asia Pacific Meningococcal Vaccines Market Overview
11.2. China
11.2.1. China Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
11.2.2. China Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
11.2.3. China Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
11.2.4. China Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.3. Japan
11.3.1. Japan Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
11.3.2. Japan Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
11.3.3. Japan Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
11.3.4. Japan Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.4. India
11.4.1. India Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
11.4.2. India Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
11.4.3. India Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
11.4.4. India Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.5. Australia
11.5.1. Australia Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
11.5.2. Australia Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
11.5.3. Australia Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
11.5.4. Australia Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.6. South Korea
11.6.1. South Korea Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
11.6.2. South Korea Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
11.6.3. South Korea Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
11.6.4. South Korea Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.7. Rest of Asia-Pacific
11.7.1. Rest of Asia-Pacific Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
11.7.2. Rest of Asia-Pacific Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
11.7.3. Rest of Asia-Pacific Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
11.7.4. Rest of Asia-Pacific Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.8. Asia Pacific PEST Analysis
CHAPTER 12. Latin America Meningococcal Vaccines Market By Country
12.1. Latin America Meningococcal Vaccines Market Overview
12.2. Brazil
12.2.1. Brazil Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
12.2.2. Brazil Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
12.2.3. Brazil Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
12.2.4. Brazil Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
12.3. Mexico
12.3.1. Mexico Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
12.3.2. Mexico Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
12.3.3. Mexico Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
12.3.4. Mexico Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
12.4. Rest of Latin America
12.4.1. Rest of Latin America Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
12.4.2. Rest of Latin America Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
12.4.3. Rest of Latin America Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
12.4.4. Rest of Latin America Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
12.5. Latin America PEST Analysis
CHAPTER 13. Middle East & Africa Meningococcal Vaccines Market By Country
13.1. Middle East & Africa Meningococcal Vaccines Market Overview
13.2. GCC
13.2.1. GCC Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
13.2.2. GCC Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
13.2.3. GCC Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
13.2.4. GCC Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
13.3. South Africa
13.3.1. South Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
13.3.2. South Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
13.3.3. South Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
13.3.4. South Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
13.4. Rest of Middle East & Africa
13.4.1. Rest of Middle East & Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By Type, 2020-2032
13.4.2. Rest of Middle East & Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By Serotype, 2020-2032
13.4.3. Rest of Middle East & Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By Age Group, 2020-2032
13.4.4. Rest of Middle East & Africa Meningococcal Vaccines Revenue (USD Billion) and Forecast By End-User, 2020-2032
13.5. Middle East & Africa PEST Analysis
CHAPTER 14. Player Analysis Of Meningococcal Vaccines Market
14.1. Meningococcal Vaccines Market Company Share Analysis
14.2. Competition Matrix
14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2. New Product Launches and Product Enhancements
14.2.3. Mergers And Acquisition In Global Meningococcal Vaccines Market
14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 15. Company Profile
15.1. Baxter International
15.1.1. Company Snapshot
15.1.2. Business Overview
15.1.3. Financial Overview
15.1.3.1. Revenue (USD Billion), 2022
15.1.3.2. Baxter International 2022 Meningococcal Vaccines Business Regional Distribution
15.1.4. Product /Service and Specification
15.1.5. Recent Developments & Business Strategy
15.2. Biomed Pvt. Ltd.
15.3. GlaxoSmithKline plc
15.4. JN-International Medical Corporation
15.5. Novartis International
15.6. Nuron Biotech
15.7. Pfizer Inc.
15.8. Sanofi SA
15.9. Walvax Biotechnology Co., Ltd.
15.10. Serum Institute of India Ltd.
Frequently Asked Questions
How big is the meningococcal vaccines market?
The meningococcal vaccines market size was USD 3.3 Billion in 2022.
What is the CAGR of the global meningococcal vaccines market from 2023 to 2032?
The CAGR of meningococcal vaccines is 8.5% during the analysis period of 2023 to 2032.
Which are the key players in the meningococcal vaccines market?
The key players operating in the global market are including Baxter International, Biomed Pvt. Ltd., GlaxoSmithKline plc, JN-International Medical Corporation, Novartis International, Nuron Biotech, Pfizer Inc., Sanofi SA, Walvax Biotechnology Co., Ltd., and Serum Institute of India Ltd.
Which region dominated the global meningococcal vaccines market share?
North America held the dominating position in meningococcal vaccines industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of meningococcal vaccines during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global meningococcal vaccines industry?
The current trends and dynamics in the meningococcal vaccines industry include increasing awareness and vaccination drives against meningococcal disease, government initiatives mandating vaccinations in certain demographics, technological advancements leading to improved vaccine efficacy, and growing healthcare expenditure and infrastructure development globally.
Which type held the maximum share in 2022?The conjugate vaccines type held the maximum share of the meningococcal vaccines industry.
Select Licence Type
Connect with our sales team
Why Acumen Research and Consulting
100%
Customer Satisfaction
24x7+
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
